Shire to Relocate Over 500 Jobs to Massachusetts

  Establishes Lexington, Mass., as U.S. Operational Headquarters; Decreases
                         Presence in Chesterbrook, Pa.

                             Interim CFO Appointed

Lexington,Mass., November19, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) today
announced plans to relocate over 500 positions to Massachusetts from its
Chesterbrook, Pennsylvania, site and establish Lexington, Massachusetts, as the
company's U.S. operational headquarters. The transition is a continuation of
the Company's `One Shire' efficiency program and will streamline business
globally through two principal locations - Massachusetts and Switzerland - with
support from a limited number of regional and country-based offices around the
world.

Simplifying operations in two principal locations will increase efficiencies
and Shire expects to realize approximately $25 million in annual savings
beginning in 2016. This site strategy will also enable greater alignment and
execution of priorities between the Company's commercial and research and
development (R&D) teams to more effectively bring innovative products to
patients, as well as strengthen collaboration and cross-development of
employees.

"Chesterbrook, the greater Philadelphia area, and the talent of our employees
based there have been instrumental to Shire's growth and evolution," said
Flemming Ornskov, M.D., Chief Executive Officer. "We've made the decision to
consolidate our U.S. operations in the Massachusetts area to streamline
operations and drive further efficiencies in the way we run our business and
serve patients. Shire has a great opportunity to combine our Chesterbrook and
Lexington talent with the leading biotech resources in the Massachusetts area,
and we consider ready access to these resources an important element in the
future growth of our company."

Shire plans to move employees in several phases beginning in the first quarter
of 2015 and targets completion by the first quarter of 2016. All directly
impacted employees who do not relocate will be offered severance, outplacement
service and other employee assistance.

Interim CFO Appointed

As previously announced, James Bowling, Interim Chief Financial Officer (CFO),
will be leaving Shire. James' departure date will now be February 28, 2015.
Jeff Poulton, Head of Investor Relations, will assume the role of interim CFO
effective January 1, 2015. The CFO position will be based in Lexington.

Jeff Poulton joined Shire in 2003 and has held leadership positions in finance
supporting the neuroscience, gastrointestinal and rare disease business units.
He oversaw the rare diseases business unit operations in North America, Latin
America, and Asia Pacific, and most recently led the integration of
Viropharma's rare disease products into the Shire portfolio.  Prior to joining
Shire, Jeff spent time at Cinergy Corp. and PPG Industries in a variety of
corporate finance and business development roles, in addition to serving four
years in the U.S. Navy as a commissioned officer.  Jeff received a Bachelor of
Arts in economics from Duke University, and a Master of Business Administration
in Finance from the Kelly School of Business at Indiana University.

For further information please contact:

Investor Relations

Jeff Poulton                            jpoulton@shire.com   +1 781 482 0945

Sarah Elton-Farr                        seltonfarr@shire.com +44 1256 894157

Media

Jessica Cotrone                         jcotrone@shire.com   +1 781 482 9538

Gwen Fisher                             gfisher@shire.com    +1 484 595 9836

Brooke Clarke                           brclarke@shire.com   +44 7808 908149


NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases,
Gastrointestinal, and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas, such as Ophthalmology.

www.shire.com


THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT
OF 1995

Statements included herein that are not historical facts are forward-looking
statements. Such forward-looking statements involve a number of risks and
uncertainties and are subject to change at any time. In the event such risks or
uncertainties materialize, Shire's results could be materially adversely
affected. The risks and uncertainties include, but are not limited to, that:

  * Shire's products may not be a commercial success;

  * revenues from ADDERALL XR are subject to generic erosion and revenues from
    INTUNIV will become subject to generic competition starting in December
    2014;

  * the failure to obtain and maintain reimbursement, or an adequate level of
    reimbursement, by third-party payors in a timely manner for Shire's
    products may impact future revenues, financial condition and results of
    operations;

  * Shire conducts its own manufacturing operations for certain of its products
    and is reliant on third party contract manufacturers to manufacture other
    products and to provide goods and services. Some of Shire's products or
    ingredients are only available from a single approved source for
    manufacture. Any disruption to the supply chain for any of Shire's products
    may result in Shire being unable to continue marketing or developing a
    product or may result in Shire being unable to do so on a commercially
    viable basis for some period of time;

  * the development, approval and manufacturing of Shire's products is subject
    to extensive oversight by various regulatory agencies. Submission of an
    application for regulatory approval of any of our product candidates, such
    as our planned submission of a New Drug Application to the FDA for
    Lifitegrast, may be delayed for any number of reasons and, once submitted,
    may be subjected to lengthy review and ultimately rejected. Moreover,
    regulatory approvals or interventions associated with changes to
    manufacturing sites, ingredients or manufacturing processes could lead to
    significant delays, increase in operating costs, lost product sales, an
    interruption of research activities or the delay of new product launches;

  * the actions of certain customers could affect Shire's ability to sell or
    market products profitably. Fluctuations in buying or distribution patterns
    by such customers can adversely impact Shire's revenues, financial
    condition or results of operations;

  * investigations or enforcement action by regulatory authorities or law
    enforcement agencies relating to Shire's activities in the highly regulated
    markets in which it operates may result in significant legal costs and the
    payment of substantial compensation or fines;

  * adverse outcomes in legal matters and other disputes, including Shire's
    ability to enforce and defend patents and other intellectual property
    rights required for its business, could have a material adverse effect on
    Shire's revenues, financial condition or results of operations;

  * Shire faces intense competition for highly qualified personnel from other
    companies, academic institutions, government entities and other
    organizations. Shire is undergoing a corporate reorganization and the
    consequent uncertainty could adversely impact Shire's ability to attract
    and/or retain the highly skilled personnel needed for Shire to meet its
    strategic objectives;

  * failure to achieve Shire's strategic objectives with respect to the
    acquisition of ViroPharma Incorporated may adversely affect Shire's
    financial condition and results of operations;

and other risks and uncertainties detailed from time to time in Shire's filings
with the Securities and Exchange Commission, including those risks outlined in
"Item 1A: Risk Factors" in Shire's Annual Report on Form 10-K for the year
ended December 31, 2013.


Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release

www.shire.com